FDA Approves Pixclara for Imaging Gliomas (Brain Cancer)

The U.S. Food and Drug Administration (FDA) has approved Pixclara (floretyrosine F 18 or 18F-FET), an amino acid positron emission tomography (PET) imaging drug for differentiating recurrent or progressive glioma from treatment-related changes in adults and pediatric patients. This marks the first FDA-approved FET-PET imaging drug for glioma, addressing a significant unmet need in brain cancer diagnostics.